Who Optimizes SG&A Costs Better? Xenon Pharmaceuticals Inc. or ACADIA Pharmaceuticals Inc.

ACADIA vs. Xenon: SG&A Cost Strategies Unveiled

__timestampACADIA Pharmaceuticals Inc.Xenon Pharmaceuticals Inc.
Wednesday, January 1, 2014327480005496000
Thursday, January 1, 2015908040009786000
Friday, January 1, 20161864560006792000
Sunday, January 1, 20172550620007313000
Monday, January 1, 20182657580008382000
Tuesday, January 1, 201932563800010803000
Wednesday, January 1, 202038866100012944000
Friday, January 1, 202139602800021967000
Saturday, January 1, 202236909000032810000
Sunday, January 1, 202340246600046542000
Loading chart...

Unveiling the hidden dimensions of data

Optimizing SG&A Costs: A Tale of Two Pharmaceuticals

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. have taken different paths in optimizing these costs. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking at approximately $402 million in 2023. In contrast, Xenon maintained a more conservative growth, with expenses increasing by around 750% to nearly $47 million in the same period.

This stark difference highlights ACADIA's aggressive expansion strategy, while Xenon appears to focus on lean operations. The data suggests that ACADIA's approach may be driven by a need to support rapid growth and market penetration, whereas Xenon prioritizes cost efficiency. As the pharmaceutical landscape evolves, these strategies will undoubtedly shape their competitive positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025